FDA Accepts First Disclosed Keytruda Biosimilar aBLA for Review

Formycon and Zydus said FDA accepted their FYB206 (pembrolizumab) aBLA for review on October 13, 2026 — the first publicly disclosed biosimilar application to Merck's Keytruda.